Aprea Therapeutics (APRE) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Traws Pharma is the larger company by market cap ($7.4 million vs $7.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | TRAW |
|---|---|---|
| Share price | $0.5582 | $0.4803 |
| Market cap | $7.03M | $7.38M |
| 1-day change | -7.74% | +0.27% |
| EPS (TTM) | $-0.95 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.69 | $3.27 |
| 52-week low | $0.548 | $0.43 |
| Distance from 52-week high | -66.97% | -85.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +568.22% | +108.20% |
| Average volume | 280.14K | 569.02K |
| Shares outstanding | 12.59M | 15.37M |
| Employees | 8 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Healthcare · Biotechnology · 8 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Healthcare · Biotechnology · 4 employees
APRE vs TRAW FAQ
Which is bigger, Aprea Therapeutics or Traws Pharma?
Traws Pharma (TRAW) is larger, with a market capitalization of $7.38M compared with $7.03M for Aprea Therapeutics (APRE).
Are Aprea Therapeutics and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.